EUVIMEDEUVIMED entdecken
Crossref

Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays

Vandana Baloda, Erin K McCreary, Breana K Goscicki, Michael R Shurin, Sarah E Wheeler iD

American Journal of Clinical Pathology · 2023

DOI: 10.1093/ajcp/aqac137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Vandana Baloda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

There is concern that the anti–severe acute respiratory syndrome coronavirus 2 therapeutic monoclonal antibodies, used as preexposure prophylaxis in patients with multiple myeloma, may appear as a detectable monoclonal protein by electrophoretic methods, resulting in misinterpretation or inability to measure therapeutic responses in some patients. In this pilot study, we characterize the effect of tixagevimab plus cilgavimab (Evusheld; T + C) on interpretation of serum protein electrophoresis (SPE), immunofixation electrophoresis (IFE), and serum free light chain (sFLC) assays.

Methods

We performed spiking experiments with T + C at serum maximum concentration following a 300-mg dose (1× Cmax) and at 10 times the concentration of Cmax (10× Cmax) with pooled serum samples. SPE and IFE technical procedures were performed on the SPIFE 3000, and sFLC and immunoglobulin G1 (IgG1) subtype quantitation was performed on the Optilite.

Results

T + C–associated interference was not visible as an M-spike in normogammaglobulinemic pooled samples. Hypogammaglobulemic pooled samples at 10× Cmax demonstrated an M-spike in SPE and immunoglobulin Gκ pattern in IFE. No increases were noted in the results of sFLC or IgG1 levels.

Conclusions

This study indicates that T + C at pharmacologic Cmax is unlikely to interfere with SPE, IFE, sFLC, or IgG1 analyses when spiked into patient serum samples, but further evaluation of recently injected patients may be warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansPilot ProjectsImmunoglobulin Light ChainsElectrophoresisAntibodies, MonoclonalImmunoglobulin G

Stichwörter der Autor:innen

Free light chain assayImmunofixation electrophoresisMultiple myelomaSerum protein electrophoresisTixagevimab plus cilgavimab

Substanzen

tixagevimabcilgavimabImmunoglobulin Light ChainsAntibodies, MonoclonalImmunoglobulin G

Autor:innen und Institutionen

  • Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Department of Pharmacy, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
  • Departments of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Departments of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Sarah E Wheeler

Zitieren

APA

Baloda, V., McCreary, E. K., Goscicki, B. K., Shurin, M. R., & Wheeler, S. E. (2023). Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqac137

Vancouver

Baloda V, McCreary EK, Goscicki BK, Shurin MR, Wheeler SE. Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqac137

BibTeX
@article{Baloda2023,
  author = {Baloda, Vandana and McCreary, Erin K and Goscicki, Breana K and Shurin, Michael R and Wheeler, Sarah E},
  title = {Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  doi = {10.1093/ajcp/aqac137}
}
Kostenlos starten →